Related Experiment Video
Updated: May 10, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Targeting cathepsin G in myeloid leukemia
1Section of Transplant Immunology; Department of Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson Cancer Center; Houston, TX USA.
Oncoimmunology
|June 5, 2013
Summary
Cathepsin G (CG), a neutrophil enzyme, is found in myeloid leukemia cells. Researchers identified CG-derived peptides targeting HLA-A*0201, offering potential for myeloid leukemia immunotherapy.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Cathepsin G (CG) is a serine protease present in neutrophil azurophil granules.
- CG expression occurs during normal myeloid differentiation and aberrantly in myeloid leukemia.
Purpose of the Study:
- To identify novel therapeutic targets for myeloid leukemia immunotherapy.
- To investigate the potential of CG-derived peptides for cancer treatment.
Main Methods:
- Identification of HLA-A*0201-binding peptides derived from Cathepsin G.
- Analysis of CG expression in myeloid leukemia cells.
Main Results:
- Successfully identified CG-derived peptides that bind to HLA-A*0201.
- These peptides show promise as targets for immunotherapy.
Conclusions:
- CG-derived HLA-A*0201-binding peptides represent a promising avenue for myeloid leukemia immunotherapy.
- Further research into these peptides could lead to new treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...